KR102838263B1 - 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질의 안정한 제제 - Google Patents
미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질의 안정한 제제Info
- Publication number
- KR102838263B1 KR102838263B1 KR1020247022666A KR20247022666A KR102838263B1 KR 102838263 B1 KR102838263 B1 KR 102838263B1 KR 1020247022666 A KR1020247022666 A KR 1020247022666A KR 20247022666 A KR20247022666 A KR 20247022666A KR 102838263 B1 KR102838263 B1 KR 102838263B1
- Authority
- KR
- South Korea
- Prior art keywords
- formulation
- pro
- myostatin
- ser
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500649P | 2017-05-03 | 2017-05-03 | |
| US62/500,649 | 2017-05-03 | ||
| PCT/US2018/030851 WO2018204617A1 (en) | 2017-05-03 | 2018-05-03 | Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin |
| KR1020197035212A KR102683806B1 (ko) | 2017-05-03 | 2018-05-03 | 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질의 안정한 제제 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197035212A Division KR102683806B1 (ko) | 2017-05-03 | 2018-05-03 | 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질의 안정한 제제 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20240113600A KR20240113600A (ko) | 2024-07-22 |
| KR102838263B1 true KR102838263B1 (ko) | 2025-07-25 |
Family
ID=62223280
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247022666A Active KR102838263B1 (ko) | 2017-05-03 | 2018-05-03 | 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질의 안정한 제제 |
| KR1020197035212A Active KR102683806B1 (ko) | 2017-05-03 | 2018-05-03 | 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질의 안정한 제제 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197035212A Active KR102683806B1 (ko) | 2017-05-03 | 2018-05-03 | 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질의 안정한 제제 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200129595A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3618809A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7157082B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102838263B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110621302A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018261154B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3062797A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL270233B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019012506A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909709SA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI897843B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018204617A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58801B1 (sr) | 2012-09-13 | 2019-07-31 | Bristol Myers Squibb Co | Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin |
| TWI897843B (zh) * | 2017-05-03 | 2025-09-21 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
| CN114681592A (zh) * | 2020-12-31 | 2022-07-01 | 天境生物科技(杭州)有限公司 | 包含可溶性gp130二聚体的制剂和使用方法 |
| TW202432577A (zh) * | 2023-02-10 | 2024-08-16 | 美商拜奧海芬治療學有限公司 | 投與基於纖連蛋白之支架域蛋白以治療超重、肥胖及相關健康病狀 |
| WO2025177263A1 (en) * | 2024-02-25 | 2025-08-28 | Biohaven Therapeutics Ltd. | Myostatin-binding proteins |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190232795A1 (en) | 2018-01-30 | 2019-08-01 | Karma Automotive, Llc | State-of-Charge Display System |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| KR100236393B1 (ko) * | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| JP2003528632A (ja) | 2000-03-31 | 2003-09-30 | インスティティ・パスツール | 血管内皮成長因子(vegf)−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法 |
| CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| US20030191187A1 (en) * | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US20070149458A1 (en) | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| AU2008345424A1 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| EP2247615B1 (en) * | 2008-02-14 | 2014-07-30 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
| CN102076713B (zh) | 2008-05-02 | 2015-03-25 | 诺华股份有限公司 | 改进的基于纤连蛋白的结合分子及其用途 |
| AR071874A1 (es) * | 2008-05-22 | 2010-07-21 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| WO2011051466A1 (en) * | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| PE20130041A1 (es) * | 2010-02-18 | 2013-01-28 | Bristol Myers Squibb Co | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| EP3091028A1 (en) * | 2010-05-26 | 2016-11-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| WO2012059486A1 (en) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2014015027A1 (en) * | 2012-07-18 | 2014-01-23 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| RS58801B1 (sr) | 2012-09-13 | 2019-07-31 | Bristol Myers Squibb Co | Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin |
| HRP20201334T1 (hr) * | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| TWI897843B (zh) * | 2017-05-03 | 2025-09-21 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
-
2018
- 2018-05-02 TW TW107114893A patent/TWI897843B/zh active
- 2018-05-03 CN CN201880029635.0A patent/CN110621302A/zh active Pending
- 2018-05-03 JP JP2019560087A patent/JP7157082B2/ja active Active
- 2018-05-03 KR KR1020247022666A patent/KR102838263B1/ko active Active
- 2018-05-03 IL IL270233A patent/IL270233B2/en unknown
- 2018-05-03 AU AU2018261154A patent/AU2018261154B2/en active Active
- 2018-05-03 CA CA3062797A patent/CA3062797A1/en active Pending
- 2018-05-03 SG SG11201909709S patent/SG11201909709SA/en unknown
- 2018-05-03 KR KR1020197035212A patent/KR102683806B1/ko active Active
- 2018-05-03 MX MX2019012506A patent/MX2019012506A/es unknown
- 2018-05-03 EP EP18726649.9A patent/EP3618809A1/en active Pending
- 2018-05-03 US US16/607,688 patent/US20200129595A1/en not_active Abandoned
- 2018-05-03 IL IL305625A patent/IL305625B2/en unknown
- 2018-05-03 WO PCT/US2018/030851 patent/WO2018204617A1/en not_active Ceased
-
2022
- 2022-10-06 JP JP2022161758A patent/JP7442595B2/ja active Active
-
2024
- 2024-07-16 AU AU2024204870A patent/AU2024204870B2/en active Active
-
2025
- 2025-04-30 US US19/194,765 patent/US20260069662A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190232795A1 (en) | 2018-01-30 | 2019-08-01 | Karma Automotive, Llc | State-of-Charge Display System |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020518603A (ja) | 2020-06-25 |
| KR20240113600A (ko) | 2024-07-22 |
| IL270233A (cg-RX-API-DMAC7.html) | 2019-12-31 |
| WO2018204617A8 (en) | 2019-01-03 |
| AU2024204870A1 (en) | 2024-08-01 |
| IL305625B1 (en) | 2024-09-01 |
| JP2023011601A (ja) | 2023-01-24 |
| US20260069662A1 (en) | 2026-03-12 |
| JP7157082B2 (ja) | 2022-10-19 |
| CA3062797A1 (en) | 2018-11-08 |
| TWI897843B (zh) | 2025-09-21 |
| AU2018261154A1 (en) | 2019-11-07 |
| AU2018261154B2 (en) | 2024-05-02 |
| EP3618809A1 (en) | 2020-03-11 |
| MX2019012506A (es) | 2019-12-19 |
| KR20200003076A (ko) | 2020-01-08 |
| CN110621302A (zh) | 2019-12-27 |
| JP7442595B2 (ja) | 2024-03-04 |
| AU2024204870B2 (en) | 2026-08-06 |
| IL270233B2 (en) | 2024-02-01 |
| WO2018204617A1 (en) | 2018-11-08 |
| IL270233B1 (en) | 2023-10-01 |
| US20200129595A1 (en) | 2020-04-30 |
| IL305625A (en) | 2023-11-01 |
| TW201842929A (zh) | 2018-12-16 |
| IL305625B2 (en) | 2025-01-01 |
| KR102683806B1 (ko) | 2024-07-11 |
| SG11201909709SA (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102424590B1 (ko) | 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질 | |
| KR102683806B1 (ko) | 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질의 안정한 제제 | |
| KR102825098B1 (ko) | 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디 | |
| JP7580404B2 (ja) | Glp1/2二重アゴニストの非経口医薬組成物 | |
| TW201740924A (zh) | 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑 | |
| CN111989121A (zh) | 高浓缩蛋白质制剂的粘度降低 | |
| CN110177567A (zh) | 含有hGH融合蛋白的治疗生长激素缺乏症的药物组合物 | |
| TW202432577A (zh) | 投與基於纖連蛋白之支架域蛋白以治療超重、肥胖及相關健康病狀 | |
| CN107849108A (zh) | 聚乙二醇化的il‑11的组合物和方法 | |
| HK40017219A (en) | Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin | |
| EP4306103B1 (en) | Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor | |
| WO2025177263A1 (en) | Myostatin-binding proteins | |
| RU2815643C2 (ru) | Фармацевтическая парентеральная композиция двойного агониста glp1/2 | |
| WO2024141054A1 (zh) | 包含融合蛋白的药物组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |